Effects of physical exercise versus rosiglitazone on endothelial function in coronary artery disease patients with prediabetes.
We conducted a three-arm, parallel-group, randomized, controlled trial to compare the effects of rosiglitazone and physical exercise on endothelial function in patients with coronary artery disease and impaired fasting glucose or impaired glucose tolerance over a 6-month period. Group A received rosiglitazone tablets 8 mg daily (n = 16), group B underwent a structured physical exercise programme (n = 15) and group C served as a control group (n = 12). At baseline and after 6 months, brachial artery ultrasound imaging was performed to assess reactive flow-mediated dilation (FMD). Rosiglitazone treatment and exercise both led to significant improvements in insulin resistance at 6 months, whereas no change was observed in control patients. FMD improved significantly in physical exercise patients, whereas no change could be observed in patients receiving rosiglitazone or in the control group. Between-group comparisons also showed a significant relative improvement in FMD in exercise patients compared with rosiglitazone.
Desch
S
S
Sonnabend
M
M
Niebauer
J
J
Sixt
S
S
Sareban
M
M
Eitel
I
I
de Waha
S
S
Thiele
H
H
Blüher
M
M
Schuler
G
G
D001786:Blood Glucose / Q000378:metabolism; D001916:Brachial Artery / Q000187:drug effects / Q000502:physiology; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology; D005081:Exercise Therapy / Q000379:methods*; D005215:Fasting / Q000097:blood; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011236:Prediabetic State / Q000188:drug therapy* / Q000503:physiopathology; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000494:pharmacology*; D016896:Treatment Outcome
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone